Dexcom, Inc. DXCM recently announced that its G6 continuous glucose monitoring (“CGM”) System is now covered by the Non-Insured Health Benefits (“NIHB”) program for diabetics aged between two and 19 ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM), is happy to share that people with type 1 diabetes who are 25 ...
SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom ...
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
SAN FRANCISCO – It's quite difficult to maintain rapid growth as a company gets very large, since it takes more to move the needle on an increasingly bigger revenue base. But continuous glucose ...
The Dexcom G7 continuous glucose monitor (CGM) is as accurate or better than other currently marketed CGM devices for measuring glucose in those with diabetes, new data from a pivotal study suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results